MyMD Pharmaceuticals Announces Corporate Changes
Ticker: QCLS · Form: 8-K · Filed: Jun 17, 2024 · CIK: 1321834
| Field | Detail |
|---|---|
| Company | Mymd Pharmaceuticals, Inc. (QCLS) |
| Form Type | 8-K |
| Filed Date | Jun 17, 2024 |
| Risk Level | medium |
| Pages | 6 |
| Reading Time | 7 min |
| Key Dollar Amounts | $0.001, $1,000, $125,000, $25,000 |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-governance, definitive-agreement, officer-changes
TL;DR
MyMD Pharma making big moves: new deals, board changes, and bylaw updates.
AI Summary
MyMD Pharmaceuticals, Inc. announced on June 13, 2024, a series of significant corporate actions. These include entering into a material definitive agreement, modifications to security holder rights, and changes in directorship and officer compensation. The company also amended its articles of incorporation or bylaws and reported other events.
Why It Matters
These changes could impact the company's governance, financial structure, and strategic direction, affecting shareholder rights and executive compensation.
Risk Assessment
Risk Level: medium — The filing indicates significant corporate restructuring and changes in governance, which can introduce uncertainty and potential risks.
Key Players & Entities
- MyMD Pharmaceuticals, Inc. (company) — Registrant
- June 13, 2024 (date) — Date of earliest event reported
- Akers Biosciences, Inc. (company) — Former company name
FAQ
What is the nature of the material definitive agreement entered into by MyMD Pharmaceuticals?
The filing does not specify the details of the material definitive agreement, only that one was entered into on or before June 13, 2024.
What specific modifications were made to the rights of security holders?
The filing indicates material modifications to the rights of security holders, but the exact nature of these modifications is not detailed in the provided text.
Were there any changes in the board of directors or executive officers?
Yes, the filing reports the departure of directors or certain officers, the election of directors, and the appointment of certain officers.
What changes were made to the company's articles of incorporation or bylaws?
The filing states that amendments to the articles of incorporation or bylaws occurred, but the specific amendments are not detailed.
When did MyMD Pharmaceuticals last change its name?
MyMD Pharmaceuticals, Inc. was formerly known as Akers Biosciences, Inc., with a name change date of April 13, 2017.
Filing Stats: 1,795 words · 7 min read · ~6 pages · Grade level 10.7 · Accepted 2024-06-17 09:04:23
Key Financial Figures
- $0.001 — ch registered Common stock, par value $0.001 per share MYMD The Nasdaq Capital M
- $1,000 — Preferred Stock, with a stated value of $1,000 per share (the "Preferred Stock"), and
- $125,000 — ntitled to (i) payment in the amount of $125,000, less all lawful and authorized withhol
- $25,000 — ments, (ii) a one-time payment equal to $25,000, less all lawful and authorized withhol
Filing Documents
- form8-k.htm (8-K) — 55KB
- ex3-1.htm (EX-3.1) — 13KB
- ex10-1.htm (EX-10.1) — 26KB
- ex10-2.htm (EX-10.2) — 36KB
- ex99-1.htm (EX-99.1) — 19KB
- 0001493152-24-024046.txt ( ) — 348KB
- mymd-20240613.xsd (EX-101.SCH) — 3KB
- mymd-20240613_lab.xml (EX-101.LAB) — 33KB
- mymd-20240613_pre.xml (EX-101.PRE) — 22KB
- form8-k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. MYMD PHARMACEUTICALS, INC. Date: June 17, 2024 By: /s/ Mitchell Glass Mitchell Glass President and Chief Medical Officer